Systemic Vascular Transduction by Capsid Mutant Adeno-Associated Virus after Intravenous Injection

Human Gene Therapy

Volumn 26, Issue 11, 2015, Pages 767-776

  Lipinski, Daniel M ^a,b   Reid, Chris A ^a   Boye, Sanford L ^a   Peterson, James J ^a   Qi, Xiaoping ^c   Boye, Shannon E ^a   Boulton, Michael E ^c   Hauswirth, William W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; NEUTRALIZING ANTIBODY; PHENYLALANINE; THREONINE; TYROSINE; VALINE; CAPSID PROTEIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CARDIOVASCULAR GENE THERAPY; CHRONIC DISEASE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; CROSS REACTION; EXPRESSION VECTOR; FLUORESCENCE MICROSCOPY; GENE TARGETING; HEK293 CELL LINE; HUMAN; IN VITRO GENE TRANSFER; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROMOTER REGION; REPORTER GENE; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; ADMINISTRATION AND DOSAGE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CYTOLOGY; DEPENDOPARVOVIRUS; ENDOTHELIUM CELL; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MUTATION; VASCULAR DISEASES;

ADMINISTRATION, INTRAVENOUS; ANIMALS; CAPSID PROTEINS; DEPENDOVIRUS; ENDOTHELIAL CELLS; GENETIC THERAPY; GENETIC VECTORS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MUTATION; TRANSDUCTION, GENETIC; VASCULAR DISEASES;

EID: 84946906911     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2015.097     Document Type: Article

References (48)

1. Hamilton SJ, and Watts GF. Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment. Rev Diabet Stud 2013;10:133-156.
2. Puddu P, Puddu GM, Zaca F, et al. Endothelial dysfunction in hypertension. Acta Cardiol 2000;55: 221-232.
3. Li H, Horke S, and Forstermann U. Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis 2014;237:208-219.
4. Hadi HA, Carr CS, and Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 2005;1: 183-198.
5. Tian XL, and Li Y. Endothelial cell senescence and age-related vascular diseases. J Genet Genomics 2014;41:485-495.
6. Schiffrin EL. Correction of remodeling and function of small arteries in human hypertension by cilazapril, an angiotensin I-converting enzyme inhibitor. J Cardiovasc Pharmacol 1996;27(Suppl 2):S13-S18.
7. Schiffrin EL, Park JB, Intengan HD, et al. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000;101:1653-1659.
8. Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001;103:799-805.
9. Prasad A, Tupas-Habib T, Schenke WH, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000;101:2349-2354.
10. McFarlane R, McCredie RJ, Bonney MA, et al. Angiotensin converting enzyme inhibition and arterial endothelial function in adults with type 1 diabetes mellitus. Diabet Med 1999;16:62-66.
11. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842-1847.
12. Quyyumi AA, Dakak N, Diodati JG, et al. Effect of L-Arginine on human coronary endotheliumdependent and physiologic vasodilation. J Am Coll Cardiol 1997;30:1220-1227.
13. Stroes E, Kastelein J, Cosentino F, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997;99:41-46.
14. Heitzer T, Krohn K, Albers S, et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus. Diabetologia 2000;43:1435-1438.
15. Higashi Y, Sasaki S, Nakagawa K, et al. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens 2002;15:326-332.
16. Pistrosch F, Passauer J, Fischer S, et al. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004;27:484-490.
17. Herweijer H, and Wolff JA. Progress and prospects: naked DNA gene transfer and therapy. Gene Ther 2003;10:453-458.
18. Bello A, Chand A, Aviles J, et al. Novel adenoassociated viruses derived from pig tissues transduce most major organs in mice. Sci Rep 2014;4:6644.
19. Chen S, Kapturczak M, Loiler SA, et al. Efficient transduction of vascular endothelial cells with recombinant adeno-Associated virus serotype 1 and 5 vectors. Hum Gene Ther 2005;16:235-247.
20. Lu ZH, Kaliberov S, Zhang J, et al. The myeloidbinding peptide adenoviral vector enables multiorgan vascular endothelial gene targeting. Lab Invest 2014;94:881-892.
21. Nettelbeck DM, Miller DW, Jerome V, et al. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol Ther 2001;3:882-891.
22. Schiedner G, Bloch W, Hertel S, et al. A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum Gene Ther 2003;14:1631-1641.
23. Manickan E, Smith JS, Tian J, et al. Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Mol Ther 2006;13:108-117.
24. Ryals RC, Boye SL, Dinculescu A, et al. Quantifying transduction efficiencies of unmodified and tyrosine capsid mutant AAV vectors in vitro using two ocular cell lines. Mol Vis 2011;17:1090-1102.
25. Petrs-Silva H, Dinculescu A, Li Q, et al. Highefficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 2009;17:463-471.
26. Kay CN, Ryals RC, Aslanidi GV, et al. Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PLoS One 2013; 8:e62097.
27. Iida A, Takino N, Miyauchi H, et al. Systemic delivery of tyrosine-mutant AAV vectors results in robust transduction of neurons in adult mice. Biomed Res Int 2013;2013:974819.
28. Qiao C, Zhang W, Yuan Z, et al. Adeno-Associated virus serotype 6 capsid tyrosine-To-phenylalanine mutations improve gene transfer to skeletal muscle. Hum Gene Ther 2010;21:1343-1348.
29. Zolotukhin S, Byrne BJ, Mason E, et al. Recombinant adeno-Associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999;6:973-985.
30. Cai J, Jiang WG, Grant MB, et al. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem 2006;281:3604-3613.
31. Boye SE, Alexander JJ, Boye SL, et al. The human rhodopsin kinase promoter in an AAV5 vector confers rod-And cone-specific expression in the primate retina. Hum Gene Ther 2012;23:1101-1115.
32. Yamashita T, Takahashi A, and Honjin R. Spatial aspect of the mouse orbital venous sinus. Okajimas Folia Anat Jpn 1980;56:329-336.
33. Hurlbut GD, Ziegler RJ, Nietupski JB, et al. Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol Ther 2010;18: 1983-1994.
34. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12:342-347.
35. Tseng YS, and Agbandje-McKenna M. Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors. Front Immunol 2014;5:9.
36. Li C, Diprimio N, Bowles DE, et al. Single amino acid modification of adeno-Associated virus capsid changes transduction and humoral immune profiles. J Virol 2012;86:7752-7759.
37. Moskalenko M, Chen L, van Roey M, et al. Epitope mapping of human anti-Adeno-Associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol 2000;74: 1761-1766.
38. Halbert CL, Miller AD, McNamara S, et al. Prevalence of neutralizing antibodies against adenoassociated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: implications for gene therapy using AAV vectors. Hum Gene Ther 2006;17:440-447.
39. Mingozzi F, Anguela XM, Pavani G, et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med 2013;5: 194ra92.
40. Stasi R, and Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004;79:504-522.
41. Mingozzi F, Chen Y, Edmonson SC, et al. Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue. Gene Ther 2013;20:417-424.
42. Monteilhet V, Saheb S, Boutin S, et al. A 10 patient case report on the impact of plasmaphe-resis upon neutralizing factors against adenoassociated virus (AAV) types 1, 2, 6, and 8. Mol Ther 2011;19:2084-2091.
43. Smith RH, Levy JR, and Kotin RM. A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields hightiter rAAV stocks from insect cells. Mol Ther 2009;17:1888-1896.
44. Clement N, Knop DR, and Byrne BJ. Large-scale adeno-Associated viral vector production using a herpesvirus-based systemenables manufacturing for clinical studies. Hum Gene Ther 2009;20:796-806.
45. Aslanidi G, Lamb K, and Zolotukhin S. An inducible system for highly efficient production of recombinant adeno-Associated virus (rAAV) vectors in insect Sf9 cells. Proc Natl Acad Sci U S A 2009;106:5059-5064.
46. Ogura T, Mizukami H, Mimuro J, et al. Utility of intraperitoneal administration as a route of AAV serotype 5 vector-mediated neonatal gene transfer. J Gene Med 2006;8:990-997.
47. Huda F, Konno A, Matsuzaki Y, et al. Distinct transduction profiles in the CNS via three injection routes of AAV9 and the application to generation of a neurodegenerative mouse model. Mol Ther Methods Clin Dev 2014;1:14032.
48. Mori S, Takeuchi T, Enomoto Y, et al. Biodistribution of a low dose of intravenously administered AAV-2, 10, and 11 vectors to cynomolgus monkeys. Jpn J Infect Dis 2006;59: 285-293.